Few operations have aroused such intense scientific scrutiny as carotid endarterectomy (CEA). Despite the provision of level I (Grade A) evidence supporting the role of CEA in symptomatic and asymptomatic patients, [1] [2] [3] [4] its role still generates widely conflicting opinions around the globe. The latest controversies relate to; (i) recent improvements in the concept of 'best medical therapy', (ii) continued scepticism about the overall generalisability of the operative risks reported in the international trials and (iii) the emergence of angioplasty as an alternative to surgery. This article will focus on an increasingly popular viewpoint (especially among stroke physicians) that improvements in best medical therapy (BMT) now render carotid surgery (and thus by implication, angioplasty) obsolete.
While the European Carotid Surgery Trial (ECST), the North American Symptomatic Carotid Endarterectomy trial (NASCET), the Asymptomatic Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial (ACST) were recruiting, the concept of BMT was relatively primitive. To many clinicians it simply meant stopping smoking, starting aspirin and treating hypertension/angina 'as best possible'. Few were prescribed lipid-lowering drugs and many hypertensive patients simply did not achieve satisfactory control of blood pressure. Moreover, the responsibility for ensuring implementation of BMT was often delegated to a junior member of the team.
So what has changed? Improvements in what currently constitutes 'modern' BMT can be summarised as; (i) alternative (dual) antiplatelet therapy, (ii) tighter thresholds and better blood pressure control using multiple drugs (especially in type II diabetics), (iii) low dose ACE inhibitor therapy and (iv) statin therapy. Each of these 'modern' agents has been evaluated in randomised trials and most have shown a 20-25% relative risk reduction (RRR) in vascular death or non-fatal myocardial infarction and stroke. [5] [6] [7] There is, therefore, no doubt that the 'modern' concept of BMT has the potential to greatly reduce long term cardiovascular risk but, in the absence of any randomised trials against CEA (and with none likely in the future), the current debate has to focus on; (i) how well is BMT tolerated or implemented in the 'real world' and (ii) how do the results from the newer medical trials compare with those of ECST, NASCET, ACAS and ACST regarding the magnitude of reduction in the absolute risk of stroke and the immediacy of benefit.
In an 'ideal' world, patients would be aware of the importance of taking their medications as prescribed, none would have side effects, all patients would have equal access to treatment, all would turn up to obtain repeat prescriptions and all medications would, of course, confer immediate benefit without requiring any lag phase. Unfortunately, we live in an imperfect world. Only 5% of diabetics think that stroke is a serious complication of their condition. 8 Only about a quarter of hypertensive patients in the US achieve a target blood pressure of !140/90 mmHg while, in some countries (e.g. England), this figure is !10%. From a practical point of view, up to 40% of known hypertensives destined to suffer a stroke will not be on any treatment in the year prior to stroke onset and only 50% of those actually receiving treatment will have one documented diastolic blood pressure !90 mmHg. 9 Similarly, while evidence suggests that multiple drug therapy for hypertension is preferable to sequential monotherapy, compliance is significantly poorer if the patient has to take more than one tablet 10 and about 50% of patients will cease their antihypertensive therapy following completion of the research trials within which they were randomised.
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The situation is no different with respect to the role of statin therapy, currently viewed by many physicians as the 'trump card' in the modern concept of BMT following publication of the British Heart Protection Study, 6 despite the fact that the most recent subgroup analysis from this trial has showed that Simvastatin did not confer any reduction in late stroke in patients with pre-existing symptomatic cerebral vascular disease. 12 In order to achieve the overall cardiovascular benefits reported in the original Heart Protection Study, 6 the patient had to be on statin therapy for 5 years. However, in the 'real world' adherence rates can be as low as 40% at 2 years in patients who have suffered an acute coronary syndrome and who might otherwise be expected to be highly motivated towards preventing further cardiovascular events. More worrying, only 17-32% of patients suffering an acute coronary event are discharged on statin therapy from the outset 13, 14 and only 50% of patients who are given a prescription will actually be taking the drug. 15 In short, secondary care clinicians (and surgeons) are generally poor at prescribing statins and implementing aggressive hypertensive therapy after heart attacks and strokes. Moreover, many patients prescribed statins or antihypertensive therapy do not get the medication from their pharmacist and most of those that do start treatment are reluctant to continue with it long term.
The inevitable 'lag phase' for BMT to exert its beneficial effect is another important but often forgotten component in the debate. It has been suggested that the frequency of haemorrhagic stroke decreases within a year of implementing optimal antihypertensive therapy, but that ischaemic stroke only starts to decline during the second year when blood pressure control thresholds are achieved. 16 In the Heart Protection Study, the reduction in stroke only became significant at the end of the second year of treatment with a statin. 12, 17 However, the median 'persistence' on statin therapy (i.e. how long continuously were the patients taking their medication) in 39,222 statin users in Umbria was only 5.3 months. 18 Simple maths shows that this is only one twelfth the length of the 5-year study period reported in the British Heart Protection Study. 6 The third factor to be considered in this debate is the actual magnitude of risk reduction and how it is reported in the literature. It has become conventional in the medical trials (especially in overviews and abstracts) to predominantly report the relative reduction in stroke or vascular risk. For the most part, the relative reduction in risk has usually been about 20-25% for stroke. In the ECST and NASCET, the equivalent RRR was 45% and 69%, respectively. 1, 2 Corresponding data for asymptomatic patients in ACAS and ACST were 54% and 45%. 3, 4 This mode of presenting RRR data can, however, be quite misleading. For example, in the Heart Protection Study, it was observed that statin therapy conferred a significant 50% RRR in the subsequent need for CEA. 6 However, if the reader looks beyond the 'headline' news, it becomes clear that the requirement for CEA in patients randomised to statin therapy was 0.4% at 5 years, as compared to 0.8% in placebo patients (pZ0.0003). The RRR conferred by statin therapy was certainly 50%, but the ARR was only 0.4% at 5 years! Accordingly, if one now compares the reductions in absolute risk of stroke by the various therapeutic options comprising the modern concept of BMT, it is possible to see just how much benefit is achievable, bearing in mind that most conferred a 20-25% RRR in stroke (Table 1) . Clopidogrel was associated with a 0.9% ARR in ischaemic stroke at 2 years in patients presenting initially with a stroke. 5 This equates to 111 patients having to be treated for 2 years to prevent one ischaemic stroke, while treating 1000 patients for 2 years would prevent only nine strokes. Interestingly, the MATCH study (Clopidogrel alone versus AspirinC Clopidogrel in patients with a prior history of stroke/ TIA) showed no evidence that combination antiplatelet therapy reduced the long-term risk of stroke. 19 Similarly, 5 years of statin therapy conferred an ARR of only 1.4% in stroke, 6 while low dose ACE-inhibitor therapy (4 mg Perindopril) conferred a 2.3% ARR in stroke at 4 years in patients who presented initially with TIA or stroke. 20 Finally, aggressive control of blood pressure in Type II diabetics was associated with a 44% reduction in stroke at 8 years but the ARR was only 3.7%. 21 How does CEA compare with regard to the reduction in absolute risk of stroke? Table 1 summarises comparable data from each of the major trials regarding the number needed to treat to prevent one stroke (NNT) and the number of strokes prevented per 1000 CEAs. In ECST, CEA conferred an ARR of 8.5% at 5 years in patients with 70-99% stenoses (NNTZ12, 83 ipsilateral ischaemic strokes prevented per 1000 operations). Parallel ARR data for NASCET patients with 70-99% stenoses (i.e. broadly equivalent to an ECST 85-99% stenosis) were 19.4% at 3 years (200 ipsilateral strokes prevented at 3 years). Carotid endarterectomy for asymptomatic disease conferred a lower ARR than in symptomatic patients (ACASZ A. R. Naylor 5.9% at 5 years, ACSTZ5.3% at five years). However, an overview of the secondary analyses from the symptomatic trials 22 has shown that one of the key advantages favouring CEA is the very much greater ARR in selected, high-risk patients (Table 1) . Carotid endarterectomy conferred a 28% ARR in stroke in NASCET patients aged over 75 with a 70-99% stenosis. In clinical terms, this means that only three patients need to undergo CEA to prevent one stroke and 303 ipsilateral strokes will be prevented per 1000 CEAs. Carotid surgery conferred an even greater benefit in patients with contralateral occlusion (ARRZ47% at 2 years) and in patients with a 90-95% stenosis and plaque irregularity/ulceration (ARRZ54% at 2 years). In both the latter subgroups, only two patients have to undergo CEA to prevent one stroke and 500 ipsilateral strokes are prevented per 1000 CEAs.
In summary, there have undoubtedly been major advances in BMT and these should be seen to complement CEA in most patients. It might be argued that BMT could threaten the role of CEA or angioplasty in asymptomatic patients, but not if the rates of persistence and compliance remain poor. Put simply, if the drugs are not being taken for sustained periods of time, they cannot confer any benefit. Moreover, BMT will never achieve comparable benefit in the more high-risk subgroups. Finally, there is one absolute reason why improvements in the 'modern concept' of BMT will not render CEA obsolete. This is, quite simply, because CEA confers immediate benefit. Best medical therapy inevitably requires a lag-phase. The Carotid Endarterectomy Triallists Collaboration (CETC) performed an overview of the pooled data from NASCET and ECST. 23 This showed that CEA conferred a 30% ARR in stroke (RRRZ80%), provided the patient was randomised within two weeks of the clinical event. On average, patients waited a further 5-7 days for surgery (P. M. Rothwell, personal communication). If surgery was delayed (for whatever reason), the overall benefit rapidly diminished (18% ARR at 3 years for patients in whom 2-4 weeks elapsed between event and randomisation, 11% ARR at 4-12 weeks and only 9% if 12Cweeks elapsed). In practical terms (i.e. taking into account the inevitable delay to operation after presentation), this essentially equates to 303 strokes being prevented at three years per 1000 CEAs if the operation is performed within one month of the most recent event as compared with only 89 strokes prevented at 3 years if surgery is delayed for O3 months after the event.
However, a surgeon cannot simply justify his/her practice on the data from the international trials without knowing and quoting his/her personal outcomes. Accordingly, an individual surgeon's operative risk is another important risk factor for stroke and has to be taken into account when deciding whether a patient is best treated by surgery or BMT. Table 2 summarises how a surgeon's operative risk modifies the effect of CEA on stroke prevention. If a surgeon performs 1000 CEAs in symptomatic patients with an operative risk of 2%, 112 ipsilateral, ischaemic strokes will be prevented at 3 years. However, if the risk were to increase to 10% (as happened to both the surgery and angioplasty arms in the CAVATAS study 24 and in patients undergoing protected angioplasty in the EVA-3S study, 25 ), only 32 strokes will be prevented at 3 years, i.e. dubious clinical benefit. Similarly, the operative risk has an equally important role in deciding whether asymptomatic patients might benefit from surgery (or angioplasty). A surgeon who performs 1000 CEAs in asymptomatic patients with an operative risk of 2% will confer a 53% RRR in late stroke and 63 strokes will be prevented at 5 years. However, if the operative risk were to increase to 6% (as was the case for both CEA and angioplasty in the SAPPHIRE study 26 ), the RRR falls to 19%, 45 procedures would have to be performed to prevent one stroke and only 22 strokes would be prevented at 5 years by operating upon 1000 patients, i.e. 978 patients would have undergone an unnecessary (and potentially dangerous) procedure.
In conclusion, the modern concept of BMT will continue to complement, rather than replace, CEA, provided; (i) someone takes responsibility for ensuring BMT is implemented properly and (ii) surgery is performed within weeks of the presenting event with a low morbidity and mortality. However, the single most important factor supporting the continued role of surgery in the future is the immediate benefit it confers. ECST, European Carotid Surgery Trial; ACST, Asymptomatic Carotid Surgery Trial. * Thirty day operative riskZdeath/any stroke within 30 days of surgery. i.e. If a surgeon has an operative risk (30-day death/stroke rate) following endarterectomy of 2%, the RRR in late stroke is 73% and 112 ipsilateral ischaemic strokes will be prevented at 3 years per 1000 CEAs performed. However, if the operative risk were as high as 10%, the RRR is now only 21% and only 32 strokes will be prevented at three years by operating upon 1000 patients.
